Summary: <br> <a href="https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.talkingbiotechpodcast.com%2F319-reprogramming-t-cells-for-immunotherapies%2F&via=talkingbiotech" class="twitter-share-button" data-size="large">Tweet</a><br> <br> <a href="https://i0.wp.com/www.talkingbiotechpodcast.com/wp-content/uploads/2021/11/319-drazan-cover.jpg"></a> T Cells are the body’snatural defenders against pathogens. In the past they have been reprogrammed to recognize specific surface antigens of cancer cells to attack and destroy them. The approach has worked well against a variety of cancers. The limitation is that they addition of genetic material is limited by transfer techniques. This episode of the Talking Biotech Podcast discusses the new approach with Dr. Ken Drazan of Arsenal Bio. They have devised a strategy to place genetic material into T-cells from an afflicted patient that can now work against the disease in question. The approach uses gene editing, adding genetic material to T cells that allows them to recognize specific antigens, such as those associated with ovarian cancer.<br> Follow on Twittter: <a href="http://www.twitter.com/ArsenalBio">@ArsenalBio</a><br>
